CUBT (Curative Biotechnology) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


What is Curative Biotechnology Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Curative Biotechnology's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

CUBT vs ORGS, SNSE, TNXP: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Curative Biotechnology's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's Margin of Safety % (DCF FCF Based) falls into.


Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.